Global Protein-expression Analysis of Bone and Soft Tissue Sarcomas

AbstractAnalysis of global protein expression, an approach known as expression proteomics, can offer important clues for understanding tumor biology that cannot be obtained by other approaches (e.g., genome or transcriptome analysis). Using two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, we performed global protein expression studies of bone and soft tissue sarcomas to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of the tumors. Among 1500 protein variants identified in the two-dimensional gel, 67 proteins correctly distinguished the eight subtypes of 99 histologically classified soft tissue sarcomas. Hierarchical clustering demonstrated leiomyosarcoma and MFH shared a similar protein expression profile, and clear cell sarcoma, synovial sarcoma, and MPNST could be grouped according to their protein expression patterns. Pleomorphic leiomyosarcoma and MFH showed similar tropomyosin isoform expression patterns. Patients with gastrointestinal stromal tumors expressing pfetin protein had better survival than those whose tumors lacked it. We identified 10 protein spots associated with the chemosensitivity of osteosarcoma to preoperative chemotherapy. These 10 spots could be new diagnostic and prognostic markers for osteosarcoma and new therapeutic targets for the disease. Proteomic analysis using 2D-DIGE provides novel information on the biology of bone and soft tissue sarcomas that could be used to diagnosis and treat these tumors. Level of Evidence: Level II, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.

[1]  David M. Thomas,et al.  Gene expression profiling of sarcomas. , 2006, Pathology.

[2]  Tadashi Kondo,et al.  Application of sensitive fluorescent dyes in linkage of laser microdissection and two‐dimensional gel electrophoresis as a cancer proteomic study tool , 2003, Proteomics.

[3]  F. Caponigro,et al.  New emerging drugs in soft tissue sarcoma. , 2006, Critical reviews in oncology/hematology.

[4]  M. Kattan,et al.  Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three‐grade system , 2005, Cancer.

[5]  M. Ladanyi Fusions of the SYT and SSX genes in synovial sarcoma , 2001, Oncogene.

[6]  S. Ferrari,et al.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[8]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[9]  L. Kindblom,et al.  Clear-cell sarcoma of tendons and aponeuroses , 2004, Virchows Archiv A.

[10]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[11]  P. Hohenberger,et al.  Osteosarcoma in Children: Long-Term Functional Analysis , 2004, Clinical orthopaedics and related research.

[12]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[13]  Y. Assaraf,et al.  Reduced folate carrier protein expression in osteosarcoma , 2003, Cancer.

[14]  M. Gebhardt,et al.  Biology and therapeutic advances for pediatric osteosarcoma. , 2004, The oncologist.

[15]  Joe C. Adams,et al.  Isolation from Cochlea of a Novel Human Intronless Gene with Predominant Fetal Expression , 2004, Journal of the Association for Research in Otolaryngology.

[16]  D. Osuna,et al.  Molecular pathology of sarcomas. , 2009, Reviews on recent clinical trials.

[17]  R. DeMatteo,et al.  Gastrointestinal stromal tumor: 5 years later , 2005, Cancer.

[18]  D. Botstein,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[19]  H. Schwartz,et al.  Proteomic Profiling in Musculoskeletal Oncology by MALDI Mass Spectrometry , 2006, Clinical orthopaedics and related research.

[20]  Piero Picci,et al.  Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. , 2005, European journal of cancer.

[21]  S. Hirohashi,et al.  Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics , 2007, Nature Protocols.

[22]  R. Grimer,et al.  Surgical options for children with osteosarcoma. , 2005, The Lancet. Oncology.

[23]  H. Inoue,et al.  Surgical management of hip dislocation in children with arthrogryposis multiplex congenita , 1998 .

[24]  A. Rydholm,et al.  Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. H. Price,et al.  Osteosarcoma in children. A study of 125 cases. , 1975, The Journal of bone and joint surgery. British volume.

[26]  G. Muschler,et al.  Prosthetic Knee Replacement after Resection of a Malignant Tumor of the Distal Part of the Femur. Medium to Long-Term Results* , 1998, The Journal of bone and joint surgery. American volume.

[27]  Ralf Janknecht,et al.  EWS-ETS oncoproteins: the linchpins of Ewing tumors. , 2005, Gene.

[28]  E. Irvine,et al.  Further studies in treatment of laryngeal papillomas with bovine wart vaccine , 1962, Cancer.

[29]  Yusuke Nakamura,et al.  Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. , 2002, Cancer research.

[30]  David E. Misek,et al.  Discordant Protein and mRNA Expression in Lung Adenocarcinomas * , 2002, Molecular & Cellular Proteomics.

[31]  T. Sano,et al.  Expression of smooth muscle markers in so called malignant fibrous histiocytomas , 2003, Journal of clinical pathology.

[32]  P. Terrier,et al.  Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Wooster,et al.  Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling , 2003, British Journal of Cancer.

[34]  S. Hirohashi,et al.  Pfetin as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics , 2008, Clinical Cancer Research.

[35]  S. Hirohashi,et al.  Proteomic signatures corresponding to histological classification and grading of soft‐tissue sarcomas , 2006, Proteomics.

[36]  B Sundell,et al.  Soft-tissue sarcomas. , 1979, British medical journal.

[37]  Yusuke Nakamura,et al.  Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. , 2004, International journal of oncology.

[38]  E. Rock,et al.  Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[39]  Tsutomu Ohta,et al.  Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma , 2007, Modern Pathology.

[40]  S. Kakar,et al.  Correlation of c‐fos, p53, and PCNA expression with treatment outcome in osteosarcoma , 2000, Journal of surgical oncology.

[41]  H. Goldschmidt,et al.  High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas , 2004, Bone Marrow Transplantation.

[42]  K. Brown,et al.  An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. , 2005, Cancer research.

[43]  Y. Hirasawa,et al.  Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma , 1998, Cancer.

[44]  F. Collin,et al.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Tsuchiya,et al.  Clear cell sarcoma of tendons and aponeuroses , 2007, Cancer.